The authors conducted a study to assess the importance of underlying liver cirrhosis in the development of hepatocellular carcinoma (HCC) and the multifactorial etiology of liver cirrhosis in chronic carriers of hepatitis B virus (HBV). Between November 1980 and May 1990, all male hepatitis B surface antigen (HBsAg) carriers who routinely attended a clinic for asymptomatic HBV carriers at the Liver Unit of Chang-Gung Memorial Hospital, Taiwan, were enrolled in the study (n = 1,506). The authors used this cohort to investigate prospectively for liver cirrhosis and HCC at 6-month intervals by means of ultrasonography and clinical assessment. There were 16 incident cases of HCC and 89 cases of liver cirrhosis (78 of whom were detected during follow-up) identified after an average follow-up of 7.1 years. Subclinical liver cirrhosis diagnosed by ultrasonography was significantly associated with the risk for HCC (multivariate-adjusted relative risk (RR) = 11.8, 95% confidence interval (Cl) 3.9-35.8). By multivariate analysis, the significant risk factors found for liver cirrhosis in HBsAg carriers were age, hepatitis B e antigen (HBeAg) carrier status, chronic hepatitis manifested by sustained elevated serum aminotransferase levels for ^6 months, cigarette smoking, non-A blood types, and low educational levels. Habitual alcohol drinking was not independently related to liver cirrhosis. However, the risk of liver cirrhosis associated with smoking was more striking among drinkers than nondrinkers (>20 cigarettes/day vs. nonsmokers: drinkers, RR = 9.3, 95% Cl 1.1-78.8; nondrinkers, RR = 1.85, 95% Cl 0.98-3.51), which suggests a possible modification effect of alcohol drinking on the liver cirrhosis risk of cigarette smoking. The authors observed synergistic effects on liver cirrhosis development for cigarette smoking with HBeAg carrier status and chronic hepatitis.
important premalignant lesion of HCC. The yearly incidence of HCC among patients with clinical liver cirrhosis ranges from 3 to 11 percent (2, 4, 5) . Although the risk of developing HCC varies greatly among patients with clinical cirrhosis due to differences in the etiology and/or the clinical stage of the disease, these data indicate that prevention of liver cirrhosis and/or identification of the extremely high risk group for chemoprevention may be crucial for reducing HCC incidence.
Chronic infection with hepatitis B virus (HBV) is a major cause of liver cirrhosis, yet only a small fraction of chronic HBV carriers may develop liver cirrhosis (6, 7) . It is widely believed that both initiation and progression of the pathogenic process of liver cirrhosis may be dependent on many predisposing factors (6, 8, 9) . Several factors have been linked to the risk of liver cirrhosis in Western countries, where the cirrhosis is most often the result of alcohol abuse (8, 9) . Alcoholic cirrhosis and chronic viral infection-related cirrhosis may have different risk factor profiles. The risk factors involved in the genesis of HBV-related cirrhosis remain to be elucidated.
In Taiwan, more than 80 percent of the patients with HCC are associated with chronic HBV infection (10) . A majority of HCC patients in Taiwan have no clinical symptoms and signs of liver cirrhosis before the time of the diagnosis of the cancer (11) , although a significant number of them may have a long-term underlying cirrhosis before the development of HCC. The importance of the association of HCC with subclinical liver cirrhosis is still obscure. We have carried out a prospective study on a large cohort of male chronic asymptomatic HBV carriers in order to monitor the development of hver cirrhosis and HCC. The aims of the present study were: 1) to establish the importance of subclinical liver cirrhosis as a risk indicator for HCC in chronic HBV carriers; and 2) to investigate the mechanisms for the transition from the chronic HBV carrier state to liver cirrhosis.
MATERIALS AND METHODS

Enrollment and follow-up
Between November 1980 and May 1990, all male hepatitis B surface antigen (HBsAg) carriers who routinely attended the clinic for asymptomatic HBV carriers at the Liver Unit of Chang-Gung Memorial Hospital were enrolled in the study if they met the following criteria: 1) they were aged 20 years or over; 2) they had no history of diagnosed HCC or liver cirrhosis (HBsAg carriers having HCC at baseline were excluded); and 3) they were willing to cooperate by visiting the clinic at scheduled intervals.
All of the study subjects were prospectively followed every 6 months, or more frequently if conditions required, until January 1994. Follow-up examinations included clinical evaluations, conventional liver-function tests, serologic markers of HBV and hepatitis D virus (HDV) infections, as well as assay for a-fetoprotein (AFP). Real-time ultrasonography was performed as a routine for the detection of cirrhosis and HCC. The causes of death of all study subjects were investigated through medical charts and data linkage with computer files of the national death registry.
Serologic evaluation
Serum markers of HBV and HDV infections, including HBsAg, hepatitis B e antigen (HBeAg), antibody to hepatitis B e antigen (anti-HBe), and antibody to hepatitis D virus (anti-HDV) were assayed by radioimmunoassay (Abbott Laboratories, North Chicago, Illinois). AFP level was measured by a-feto-RIA-II (Dainabot, Tokyo, Japan). Conventional hver function tests were performed with a sequential multiple autoanalyzer.
Life-style habits
Information about sociodemographic characteristics and cigarette smoking and alcohol drinking habits were obtained at the time of enrollment through interviews by well-trained research assistants using a structured questionnaire. Because the average quantity of alcohol consumed by Chinese is not large in Taiwan, habitual alcohol drinking was defined as consumption of any alcoholic beverage at least once a week for more than one year.
Detection of liver cirrhosis
Status of liver cirrhosis among asymptomatic HBsAg carriers in this study was determined on the basis of ultrasound scanning. Ultrasonography was performed using a high-resolution, real-time scanner (model SSD-256, SSD-630, SSD-650, Aloka Co., Ltd., Tokyo, Japan) equipped with 3.5 MHz and 5.0 MHz rectilinear array or convex scan probes. Study subjects were scored quantitatively for ultrasonographic features of liver surface, liver parenchyma, hepatic vessel, and spleen size according to a scoring system described previously (12) . Individuals with ultrasonograms showing a score of ^8 were considered to have hver cirrhosis. Each physician in this prospective study was trained similarly with respect to the scoring system for the diagnosis of liver cirrhosis. Both intraobserver and interobserver variation calculated by the coefficients of variation for the use of the scoring system was less than 10 percent.
Diagnosis of HCC
Subjects with either focal lesions on ultrasound examination or elevated AFP levels (^20 ng/ml) were further examined with computed tomography, hepatic arteriography, and/or fine-needle aspiration biopsy. A final diagnosis of HCC was based on either histologic/ cytologic findings or elevated AFP levels >400 ng/ml combined with at least one positive liver image on arteriography, sonography, and/or computed tomography.
Statistical analysis
Relative risks and their 95 percent confidence intervals were estimated by Cox's proportional hazards regression model using the SAS statistical package (SAS Institute, Cary, North Carolina). The period of observation used in calculating relative risk began at the date of enrollment and ended at the date of diag-nosis of the disease or the date of last clinic visit. Time-dependent variables were used to model the effect of liver cirrhosis and chronic hepatitis manifested by sustained elevated serum aminotransferase levels on the risk of HCC and the effect of chronic hepatitis on the liver cirrhosis risk. The change in the status of these variables was defined by the time-dependent covariate function z(t), which took the value 1 or 0 at time t depending on whether or not the subject had been diagnosed as having liver cirrhosis/ chronic hepatitis at that time. The onset time of chronic hepatitis was measured from the date of the first appearance of elevated serum aminotransferase level during the course of prolonged necroinflammatory activity of the liver. All reported p values are two-tailed.
RESULTS
Characteristics at enrollment
A total of 1,506 HBsAg carriers met the study criteria and were enrolled. Table 1 shows the characteristics of the study subjects at the baseline examination. More than 60 percent of subjects were less than 40 years old at entry to the study. Sixty-three percent of the subjects had an educational level of senior high school and above. The distribution of ABO blood types in the study subjects was similar to that previously reported in a Chinese population (13) . Fortythree percent of subjects were cigarette smokers, and only 21.2 percent were habitual alcohol drinkers. More than 90 percent of the habitual alcohol drinkers reported consumption of alcohol at least once a week for >5 years (data not shown).
Among the 1,506 study subjects, 297 (19.7 percent) were HBeAg-positive; 1,152 (76.5 percent) were HBeAg-negative and anti-HBe-positive; 50 (3.3 percent) tested negative for both HBeAg and anti-HBe; and only 7 (0.5 percent) who tested negative for HBeAg had unknown status for anti-HBe. A total of 509 subjects (33.8 percent) had elevated serum alanine aminotransferase (ALT) levels and 427 (28.4 percent) had increased aspartate aminotransferase (AST) levels. An abnormally high AFP level (^20 ng/ml) was found in only 49 subjects (3.3 percent). At initial ultrasound examination, 11 subjects (0.7 percent) were diagnosed as having liver cirrhosis.
Follow-up
The mean duration (standard deviation) of follow-up was 7.1 (2.8) years. More than 75 percent of the subjects were followed up every 6 months by medical examination for more than 5 years, and only 1 percent were followed up for one year or less. A total of 28 deaths were observed. There were 14 deaths attributable to HCC. Serum levels of AFP remained within the normal range in 1,298 subjects (86.2 percent), fluctuated between normal and elevated value in 195 (12.9 percent), and were persistently elevated in 13 (0.9 percent). Liver cirrhosis was diagnosed during the follow-up in 78 subjects on the basis of ultrasound assessment, yielding a yearly incidence rate of 0.7 percent. The serum albumin levels of all the cirrhotic patients in this study were within normal range at the time of diagnosis of the cirrhosis. Their serum bilirubin levels were lower than 1.0 mg/dl or slightly increased up to 2.0 mg/dl at diagnosis. Only one of the cirrhotic patients died of liver cirrhosis throughout the study. One subject without evidence of cirrhosis before loss of follow-up died of liver cirrhosis 2.5 years after withdrawal. HCC was detected in 16 subjects (of whom 7 subjects had liver cirrhosis diagnosed by ultrasonography). All of the patients with liver cirrhosis identified by ultrasonography in whom HCC developed remained asymptomatic until the diagnosis of the cancer. Table 2 shows the results of the Cox's regression analysis performed to examine the relation between clinical risk factors and HCC incidence in HBsAg carriers. After adjustment for known HCC risk factors and other clinical risk factors, elevated serum AFP levels and liver cirrhosis on ultrasound scanning were significant predictors for the development of HCC in chronic HBV carriers. The association between elevated serum aminotransferase levels lasting for 6 months or longer and risk of HCC was marginally significant (p -0.06). A nonsignificant negative association was observed between the seropositivity of HBeAg and HCC.
Clinical predictors for HCC
Multiple risk factors and liver cirrhosis
The associations with the development of liver cirrhosis for multiple risk factors were further analyzed. The 11 subjects who had liver cirrhosis at the initial ultrasound examination were excluded from the following analyses. Status of anti-HDV was determined during follow-up in 1,335 subjects. The positive rate of anti-HDV was 2.8 percent. The incidence of liver cirrhosis was lower in anti-HDV-positive subjects (1/38) than in anti-HDV-negative subjects (72/1,297). Because only one anti-HDV-positive subject developed cirrhosis, anti-HDV status was not included in the raultivariate analyses.
To check if there may be a monotonic association between age and the incidence of liver cirrhosis, age at recruitment was first divided into four levels: 20-29, t One subject without information on alcohol drinking and three subjects with missing data on educational level were not included in the multivariate analysis. Interaction of cigarette smoking with other risk factors Table 4 shows the risk of liver cirrhosis in relation to cigarette smoking among drinkers and nondrinkers. The risk associated with cigarette smoking was more striking among drinkers than nondrinkers (^20 cigarettes/day vs. nonsmokers: drinkers, RR = 9.3, 95 percent CI 1.1-78.8; nondrinkers, RR = 1.85, 95 percent CI 0.98-3.51), which suggests a possible modification effect of alcohol drinking on the liver U Adjusted for age at recruitment, elevation of serum aminotransferase for at least 6 months, habitual alcohol drinking, educational levels, and blood types.
DISCUSSION
The main mechanism for chronic infection with HBV to predispose individuals to HCC might be through the chronic necroinflammation and regenerative proliferation (10) . It has been well established that clinical liver cirrhosis is a significant determinant for the development of HCC (2, 4, 5) . In this study, the role of subclinical cirrhosis as a risk indicator for HCC was prospectively investigated in a large series of chronic asymptomatic HBsAg carriers. Our data indicate that liver cirrhosis diagnosed on the basis of ultrasound examination is a major risk factor for HCC among chronic HBV carriers. Multivariate analysis showed that the HBV carriers with liver cirrhosis on ultrasound scanning had a relative risk of HCC approximately 12 times greater than that of those with ultrasonograms negative for liver cirrhosis. Serum AFP is sometimes high in patients who have liver cirrhosis without HCC (4, 6) . Although the observed significant association between liver cirrhosis and HCC in chronic HBV carriers might be the result of more intensive or careful examination among persons who have elevated AFP and/or ultrasound evidence of liver cirrhosis, ultrasonography is widely accepted as an effective procedure for early detection of HCC in patients whose serum level of AFP may be within the normal range (1,2, 5). Furthermore, each asymptomatic HBsAg carrier was followed up by ultrasonography and clinical assessment at 6-month intervals. It is therefore reasonable to speculate that the strong association of liver cirrhosis with HCC in this study is unlikely to be explained by the detection bias due to a differential effort made in the diagnosis of HCC among those with and without liver cirrhosis.
Liver biopsy currently is considered to establish the precise diagnosis of liver cirrhosis. However, this procedure is relatively invasive and thus could not be used in this study. It was reported that patients with liver cirrhosis of different etiologies may have different sonographic characteristics of the liver (12, 14) . The usefulness of ultrasonography in the diagnosis of liver cirrhosis in patients with chronic hepatitis B has been established (12) . Although a fraction of subclinical cirrhosis may not be diagnosed by ultrasonography in this study, the extremely high HCC risk observed for patients with ultrasonographic evidence of liver cirrhosis suggests that it is a useful diagnostic tool. Periodical assessment by means of ultrasonography may be valuable for the noninvasive investigation of liver cirrhosis in asymptomatic HBV carriers. Moreover, it may provide a means to identify a subgroup of such carriers who are at high risk for HCC.
Based on histologic findings, previous reports (7, 15) indicate that approximately 1 percent of asymptomatic HBV carriers have liver cirrhosis. The results of our prospective study indicate that only a small fraction of chronic asymptomatic HBV carriers (0.74 percent annually) might develop liver cirrhosis even after a long-term follow-up. We thus further investigated the determinants for the transition from chronic HBV carrier state to liver cirrhosis. In multivariate analysis, the significant risk factors that we found to be associated with cirrhosis in chronic HBV carriers were aging, HBeAg carrier status, sustained elevated serum aminotransferase levels for ^6 months, cigarette smoking, low educational levels, and non-A blood types.
The importance of aging for the development of liver cirrhosis in patients with chronic hepatitis B has been reported (6) . The significance of increasing age as a risk factor may reflect the prolonged duration of the underlying liver diseases and/or the accumulation of exposure to environmental risk factors associated with liver cirrhosis.
Elevated serum aminotransferases levels were considered to be an indicator of activity of hepatitis. The strong association of cirrhosis risk with sustained elevated serum aminotransferase levels for >6 months found in this study strengthens the argument that continuous destruction of liver tissue through prolonged necroinflammatory activity plays an important role in the development of cirrhosis. In addition, more than 60 percent of the chronic HBV carriers in whom liver cirrhosis developed were observed to have biochemical evidence of chronic hepatitis before the onset of cirrhosis, which indicated that the progression from chronic hepatitis to liver cirrhosis may be the most common pathway that leads to liver cirrhosis in asymptomatic HBV carriers.
HBeAg is associated with active HBV replication and underlying liver disease (16) (17) (18) (19) (20) . In this study, HBeAg carrier status was associated with an increased risk of liver cirrhosis, while the relation of HBeAg to HCC was not statistically significant. The prevalence of HBeAg decreased and the anti-HBe prevalence increased with increasing age in chronic HBV carriers. It has been demonstrated (21) that seroconversion from HBeAg to anti-HBe in most HCC patients in Taiwan occurs years before development of the cancer. On the other hand, hepatocellular damage may concur with the clearance of HBeAg (22) . Thus the discrepancy in the association with HBeAg observed for liver cirrhosis and HCC may be due to the fact that HCC is a sequel of liver cirrhosis. The results of the present work are not only in support of a role of HBeAg carrier status in the development of liver cirrhosis, but also demonstrate a synergistic interaction between the carrier status of HBeAg and cigarette smoking in risk of liver cirrhosis.
Due to the small number of HCC cases we did not find that cigarette smoking was a significant risk factor for HCC in this study. However, a significant association between cigarette smoking and risk of HCC has been observed in our previous epidemiologic studies ( [23] [24] [25] . The root mechanism responsible for the action of cigarette smoking in hepatocarcinogenesis is not well understood. It has been reported that cigarette smoking may be a significant risk factor for the development of alcoholic cirrhosis (8) . This study suggests that cigarette smoking may intensify the pathogenesis of liver cirrhosis caused by persistent HBV infection either independently and/or through an interactive effect with other risk factors. Cigarette smoke contains a number of toxic substances. An animal study (26) has demonstrated that long-term exposure to cigarette smoke causes liver degeneration and necrosis. The effect of cigarette smoking on immunity to HBV has not been stressed in previous investigations. However, there is evidence that cigarette smoking may induce diverse alterations in the immune system (27) (28) (29) . Although the precise mechanism for the association between cigarette smoking and liver cirrhosis is unclear, this study suggests that intervention against cigarette smoking is important for the prevention of liver cirrhosis in chronic HBV carriers, especially among those carriers who are positive for HBeAg and/or among patients with chronic hepatitis.
Alcohol consumption is the most prevalent cause of liver cirrhosis in Western countries (8, 30) . In this study, the average quantity of alcohol intake among habitual alcohol drinkers was only 175 g/week. This amount may be insufficient to induce liver cirrhosis. Habitual alcohol drinking was not observed to be independently related to the risk of cirrhosis in chronic HBV carriers; however, it seemed to have a strong modification effect on the cirrhosis risk in relation to cigarette smoking. In addition to the hepatotoxic effect, it is noteworthy that alcohol consumption has an inducing effect on microsomal enzymes that metabolize many chemicals in cigarette smoke to toxic substances (31) . Whether this may explain the modification effect of habitual alcohol drinking on risk of cigarette smoking-related cirrhosis observed in this study requires further study.
Although we observed a significant association between non-A blood types and the risk of liver cirrhosis, we can provide no clear explanation for this finding. The relation of low educational level to increased risk of cirrhosis is sufficiently strong that chance is an unlikely explanation. This association was independent of cigarette smoking and habitual alcohol drinking. It is therefore essential to look for other risk/ protective factors in order to understand the precise mechanism responsible for the pathogenesis of liver cirrhosis in chronic HBV carriers.
Infections with other viruses may interact with HBV and thus increase the risk of liver cirrhosis. Hepatitis C virus (HCV) has been documented to be an etiologic factor for liver cirrhosis (9, 10, 32) . However, the importance of HCV infection for the development of liver cirrhosis in chronic HBV carriers was not investigated in this study. Because the prevalence of antibodies against HCV was lower than 2 percent in the general population in Taiwan (33) , even if HCV is also a significant risk factor involved in the genesis of HBV-related liver cirrhosis, it may not contribute in any important way to the etiology of liver cirrhosis in Taiwan. HDV has also been documented to be associated with advanced chronic liver disease (34) . It has been reported (35) that most of the HDV superinfections in Taiwan are caused by genotype II HDV, which is associated with less aggressive course of HDV infections. The low prevalence of anti-HDV in this study is consistent with previous data from Taiwan (36) . The results of the present study confirm our earlier finding (6) that HDV superinfection was not a significant risk factor for cirrhosis among patients with chronic hepatitis B. Because the positive rate of anti-HDV was low, the role of HDV in the development of liver cirrhosis needs a larger sample size of HBV carriers and longer period of follow-up for clarification.
